IL142942A0 - Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other toga viruses - Google Patents

Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other toga viruses

Info

Publication number
IL142942A0
IL142942A0 IL14294299A IL14294299A IL142942A0 IL 142942 A0 IL142942 A0 IL 142942A0 IL 14294299 A IL14294299 A IL 14294299A IL 14294299 A IL14294299 A IL 14294299A IL 142942 A0 IL142942 A0 IL 142942A0
Authority
IL
Israel
Prior art keywords
metabolites
hepatitis
precursors
virus
derivatives
Prior art date
Application number
IL14294299A
Original Assignee
Holis Eden Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holis Eden Pharmaceuticals Inc filed Critical Holis Eden Pharmaceuticals Inc
Publication of IL142942A0 publication Critical patent/IL142942A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IL14294299A 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other toga viruses IL142942A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10992498P 1998-11-24 1998-11-24
US12408799P 1999-03-11 1999-03-11
US12605699P 1999-03-23 1999-03-23
PCT/US1999/028082 WO2000032177A2 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections

Publications (1)

Publication Number Publication Date
IL142942A0 true IL142942A0 (en) 2002-04-21

Family

ID=27380740

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14294299A IL142942A0 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other toga viruses
IL142942A IL142942A (en) 1998-11-24 2001-05-03 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof for manufacture of medicaments for use in the treatment of hepatitis c virus and other toga viruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142942A IL142942A (en) 1998-11-24 2001-05-03 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof for manufacture of medicaments for use in the treatment of hepatitis c virus and other toga viruses

Country Status (14)

Country Link
EP (1) EP1133287A2 (en)
JP (1) JP2002531397A (en)
KR (1) KR20010101074A (en)
CN (1) CN1328463A (en)
AP (1) AP2001002181A0 (en)
AU (1) AU775614B2 (en)
BR (1) BR9915644A (en)
CA (1) CA2352205A1 (en)
HK (1) HK1042426A1 (en)
ID (1) ID29864A (en)
IL (2) IL142942A0 (en)
NZ (1) NZ511721A (en)
OA (1) OA11716A (en)
WO (1) WO2000032177A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
CA2375647A1 (en) 1999-07-08 2001-01-18 Patrick T. Prendergast Use of flavones, coumarins and related compounds to treat infections
DK1955700T3 (en) 1999-09-30 2011-05-23 Harbor Biosciences Inc Therapeutic treatment of androgen receptor-related disorders
US8476254B2 (en) 2002-07-02 2013-07-02 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferson-α therapy
EP2298315A1 (en) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
KR101435242B1 (en) * 2007-11-15 2014-08-29 마다우스 게엠베하 Silibinin component for the treatment of hepatitis
CN102993148B (en) * 2011-09-13 2015-12-09 复旦大学 Quercetin derivative or its analogue and application thereof
WO2013178782A1 (en) * 2012-05-30 2013-12-05 Universidad De Zaragoza Allosteric inhibitors of ns3 protease from hepatitis c virus
CN108003212A (en) * 2017-12-24 2018-05-08 扬州工业职业技术学院 A kind of dehydroepiandros-sterone -6- glucoside derivatives and its application as anti hepatitis C virus drug
CN110452280B (en) * 2019-07-25 2020-11-17 中国人民解放军第二军医大学 Tetracyclic triterpenic acid derivative and preparation method and application thereof
JP2023543352A (en) * 2020-09-22 2023-10-13 マイクロナイゼーション テクノロジーズ アンド セラピューティクス グループ エルエルシー Nebulizers and atomized antivirals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (en) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof.
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
EP0901375A1 (en) * 1996-04-17 1999-03-17 Patrick Thomas Prendergast Dhea combination therapy
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Also Published As

Publication number Publication date
EP1133287A2 (en) 2001-09-19
BR9915644A (en) 2001-08-07
OA11716A (en) 2005-01-25
NZ511721A (en) 2004-07-30
AP2001002181A0 (en) 2001-05-24
ID29864A (en) 2001-10-18
AU3105200A (en) 2000-06-19
KR20010101074A (en) 2001-11-14
AU775614B2 (en) 2004-08-05
JP2002531397A (en) 2002-09-24
CA2352205A1 (en) 2000-06-08
WO2000032177A3 (en) 2001-03-22
HK1042426A1 (en) 2002-08-16
IL142942A (en) 2006-08-20
WO2000032177A2 (en) 2000-06-08
CN1328463A (en) 2001-12-26

Similar Documents

Publication Publication Date Title
PL344223A1 (en) Compositions for the treatment of hiv and other viral infections
NZ290318A (en) Compositions comprising antisense oligonucleotides for use against hepatitis b viral replication
HK1097413A1 (en) Compositions comprising viruses and methods for concentrating virus preparations
SG10201710373RA (en) Methods and compositions for treating hepatitis c virus
AU2002330154A1 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
HK1037981A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C.
EP1128832A4 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
FI950709A (en) Organometallic fluorenyl compounds, preparation and use
HUP9900389A3 (en) Mixture of recombinant viruses as polyenv vaccines for hiv, preparation and use thereof
EE9700044A (en) Heteroaryloxazolidinones, process for their preparation, use in the manufacture of medicaments and medicaments containing these compounds.
IL129352A0 (en) Benzimidazole-2- carbamates for the treatment of viral infections and cancer
ZA97721B (en) Methods for retreatment of patients afflicted with hepatitis C using consensus interferon.
EP1322325A4 (en) Inhibiting hepatitis c virus processing and replication
ZA200202816B (en) Modified plant viruses and methods of use thereof.
IL142942A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other toga viruses
AU2158000A (en) Treatment of hepatitis c virus infections with interleukin-10
HUP0100087A3 (en) Nucleosides analogues, the use thereof for producing medicaments useful against retroviral infections and hepatitis b virus and the same medicaments
HK1046428A1 (en) The genome of the hiv-1 inter-subtype (c/b') and use thereof
IL142941A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of african and american trypanosomiasis
EP1106599A4 (en) Chromium l-threonate, process for preparation of the same and their use
AU4132096A (en) Compositions and methods for interfering with hepatitis b virus infection
AU2001234596A1 (en) Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
GB2351904B (en) Herbal composition and use of the composition for treating viral infection of the liver
AU5397498A (en) Sequences derived from the genome of the c hepatitis virus, and use thereof
HUP9900123A3 (en) 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed